NEW YORK, NY / ACCESSWIRE / April 24, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
AVEO Pharmaceuticals, Inc. (AVEO)
Class Period: August 4, 2016 - January 31, 2019
Lead Plaintiff Deadline : April 26, 2019
Join the action: https://www.zlk.com/pslra-1/aveo-pharmaceuticals-inc-loss-form?prid=1257&wire=1
Allegations: AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.
To learn more about the AVEO Pharmaceuticals, Inc. class action contact firstname.lastname@example.org.
The Kraft Heinz Company (KHC)
Class Period: July 6, 2015 - February 21, 2019
Lead Plaintiff Deadline : April 25, 2019
Join the action: https://www.zlk.com/pslra-1/the-kraft-heinz-company-loss-form?prid=1257&wire=1
Allegations: The Kraft Heinz Company made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants misrepresented that the Zero Based Budgeting (“ZBB”) and other cost-saving measures would deliver increased profitability while simultaneously maintaining base business momentum; (ii) Defendants failed to disclose known trends that were negatively impacting the Company’s organic sales growth and profitability; (iii) Defendants falsely represented the ability of the Company’s pipeline of new products to generate organic growth; (iv) Defendants falsely stated that “main-stays like Oscar Mayer [and] Kraft cheese” were “tangible drivers of [a] turnaround in the second half of 2018”; (v) Defendants failed to disclose known trends that resulted in the intangible asset impairments associated with the Company’s Oscar Mayer and Kraft brands; and (vi) Defendants failed to disclose known trends that resulted in the goodwill impairments affecting its U.S. Refrigerated and Canada Retail divisions.
To learn more about the The Kraft Heinz Company class action contact email@example.com.
Vanda Pharmaceuticals Inc. (VNDA)
Class Period: November 4, 2015 - February 11, 2019
Lead Plaintiff Deadline : April 26, 2019
Join the action: https://www.zlk.com/pslra-1/vanda-pharmaceuticals-inc-loss-form?prid=1257&wire=1
Allegations: During the class period, Vanda Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Vanda was engaged in a fraudulent scheme in which it promoted the off-label use of Fanapt and Hetlioz; (2) Vanda was fraudulently receiving drug reimbursements from the government by abusing Medicare, Medicaid, and Tricare programs; (3) as a result of the scheme, Vanda faced legal action from the government; (4) Vanda’s promotional materials for Fanapt and Hetlioz were false and misleading, garnering regulatory scrutiny from the U.S. Food and Drug Administration; and (5) as a result, defendants’ statements about Vanda’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Vanda Pharmaceuticals Inc. class action contact firstname.lastname@example.org.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: